BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+7.78%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.01B
AUM Growth
+$119M
(+1.7%)
Cap. Flow
-$225M
Cap. Flow
% of AUM
-3.21%
Top 10 Holdings %
Top 10 Hldgs %
36.63%
Holding
168
New
9
Increased
52
Reduced
52
Closed
12
Top Buys
| 1 |
Eli Lilly
LLY
|
$39.6M |
| 2 |
Evolent Health
EVH
|
$38.1M |
| 3 |
Merck
MRK
|
$34.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$27.1M |
| 5 |
Humana
HUM
|
$26.3M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$53.8M |
| 2 |
Sarepta Therapeutics
SRPT
|
$51.1M |
| 3 |
HCA Healthcare
HCA
|
$43.5M |
| 4 |
Intuitive Surgical
ISRG
|
$43.3M |
| 5 |
Boston Scientific
BSX
|
$42.1M |
Sector Composition
| 1 | Healthcare | 99.05% |
| 2 | Industrials | 0.87% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
ESSA Pharma
EPIX
$11.2M
| $21.3M | 0.3% |
7,898,583
| – | – |
|
77
Generation Bio
GBIO
$40.3M
| $19.9M | 0.28% |
362,028
| – | – |
|
78
Phreesia
PHR
$1.81B
| $19.8M | 0.28% |
638,653
| – | – |
|
79
Centene
CNC
$14.8B
| $19.7M | 0.28% |
292,527
-256,814
| -47% | -$17.3M |
|
80
Supernus Pharmaceuticals
SUPN
$2.52B
| $19.5M | 0.28% |
650,256
+527,375
| +429% | +$15.9M |
|
81
Legend Biotech
LEGN
$6.64B
| $19M | 0.27% |
275,754
-231,500
| -46% | -$16M |
|
82
10x Genomics
TXG
$1.66B
| $18.1M | 0.26% |
324,746
| – | – |
|
83
Mersana Therapeutics
MRSN
$34.8M
| $17.2M | 0.24% |
208,777
+36,792
| +21% | +$3.03M |
|
84
Wave Life Sciences
WVE
$1.27B
| $16.4M | 0.23% |
4,494,458
| – | – |
|
85
Scholar Rock
SRRK
$3.3B
| $16.1M | 0.23% |
2,140,025
| – | – |
|
86
Illumina
ILMN
$15.2B
| $15.8M | 0.22% |
86,379
-15,657
| -15% | -$2.86M |
|
87
Castle Biosciences
CSTL
$673M
| $15.4M | 0.22% |
1,124,043
+175,165
| +18% | +$2.4M |
|
88
Doximity
DOCS
$12.6B
| $15.3M | 0.22% |
448,579
| – | – |
|
89
Cigna
CI
$80.2B
| $14.1M | 0.2% |
50,399
-3,077
| -6% | -$863K |
|
|
VRNA
90
Verona Pharma
VRNA
$9.18B
| $12.1M | 0.17% |
572,315
+309,632
| +118% | +$6.55M |
|
91
Regeneron Pharmaceuticals
REGN
$59.8B
| $11.7M | 0.17% |
16,327
+1,011
| +7% | +$726K |
|
|
PNT
92
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $11.4M | 0.16% |
+1,256,197
| New | +$11.4M |
|
93
Natera
NTRA
$23B
| $11.3M | 0.16% |
232,775
| – | – |
|
94
Teladoc Health
TDOC
$1.37B
| $9.93M | 0.14% |
392,264
-40,457
| -9% | -$1.02M |
|
95
Baxter International
BAX
$12.1B
| $9.72M | 0.14% |
213,434
-60,180
| -22% | -$2.74M |
|
96
Gilead Sciences
GILD
$140B
| $8.68M | 0.12% |
112,650
+12,294
| +12% | +$947K |
|
97
Biogen
BIIB
$20.5B
| $7.29M | 0.1% |
25,598
+894
| +4% | +$255K |
|
98
AstraZeneca
AZN
$255B
| $6.13M | 0.09% |
85,600
+14,000
| +20% | +$1M |
|
99
Amgen
AMGN
$153B
| $6.06M | 0.09% |
27,310
-11,057
| -29% | -$2.45M |
|
100
Esperion Therapeutics
ESPR
$490M
| $5.85M | 0.08% |
4,208,264
| – | – |
|